First patient enrolled in pivotal Phase III clinical study SPARKLE with lead candidate Mangoral
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the first patient has been enrolled in the company’s global pivotal Phase III clinical study SPARKLE with Mangoral in patients with severely reduced renal function and with known or suspected liver lesions.“It is an important event for patients seeking a safe agent to detect liver lesions that this pivotal Phase III study is now enrolling study subjects. We see the interest from premier hospitals and expert doctors to participate as a testimony to the unique potential offered by Mangoral and the large unmet medical need for these